 |
Jul 28, 2010 |
Vertex Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress
|
27.0 KB |
|
| |
CAMBRIDGE, Mass., Jul 28, 2010 (BUSINESS WIRE) -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update
on recent progress in its development programs in hepatitis C virus
(HCV) infection, cystic fibrosis (CF) and other diseases and reported
consolidated financial results for the quarter ended J...
|
|
|
Jul 13, 2010 |
Vertex Pharmaceuticals Appoints Wayne J. Riley, M.D., to its Board of Directors
|
8.4 KB |
|
| |
CAMBRIDGE, Mass., Jul 13, 2010 (BUSINESS WIRE) -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Wayne J. Riley, M.D., M.B.A., joined its board of directors as an
independent director. The addition of Dr. Riley brings the number of
Vertex board members to 10. Dr. Riley was appointed to the cl...
|
|
|
Jul 12, 2010 |
Vertex Pharmaceuticals Announces the Date of its Second Quarter 2010 Financial Results Conference Call and Webcast
|
6.0 KB |
|
| |
CAMBRIDGE, Mass., Jul 12, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its
second quarter 2010 financial results on Wednesday, July 28, 2010 after
the financial markets close. The Company will host a conference call at
5:00 p.m. EDT.
The conference call will be webcast live and ma...
|
|
|
Jun 11, 2010 |
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences
|
6.2 KB |
|
| |
CAMBRIDGE, Mass., Jun 11, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
it will webcast its presentations at the Goldman Sachs 31st
Annual Global Healthcare Conference on Wednesday, June 16, 2010 at 2:40
p.m. PDT (5:40 p.m. EDT), at the NASDAQ OMX 24th Investor
Progra...
|
|
|
Jun 1, 2010 |
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
6.3 KB |
|
| |
CAMBRIDGE, Mass., Jun 01, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
it will webcast its presentations at the Sanford C. Bernstein Strategic
Decisions 2010 Conference on Thursday, June 3, 2010 at 9:00 a.m. EDT and
at the 9th Annual Needham Healthcare Conference on Wednesda...
|
|
|
May 25, 2010 |
75% of Treatment-Naïve Patients with Chronic Hepatitis C Achieve SVR (Viral Cure) with Telaprevir-Based Treatment in Phase 3 Trial
|
24.3 KB |
|
| |
CAMBRIDGE, Mass., May 25, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
75% of people chronically infected with genotype 1 hepatitis C virus
(HCV) who had not previously been treated achieved a sustained viral
response (SVR or viral cure) after receiving a 12-week telaprevir-...
|
|
|
May 13, 2010 |
Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
|
6.6 KB |
|
| |
CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results
of the voting at its 2010 Annual Meeting of Shareholders.
At the meeting, shareholders re-elected director nominees Dr. Joshua
Boger, Dr. Charles A. Sanders and Elaine S. Ullian. Their terms will
...
|
|
|
Apr 27, 2010 |
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
6.1 KB |
|
| |
CAMBRIDGE, Mass., Apr 27, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
it will webcast its presentations at the Deutsche Bank 35th Annual
Health Care Conference on Tuesday, May 4, 2010 at 3:30 p.m. EDT and at
the Bank of America Merrill Lynch Health Care Conference on Tuesda...
|
|
|
Apr 21, 2010 |
Vertex Pharmaceuticals Reports First Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress
|
26.8 KB |
|
| |
CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update
on recent progress in its development programs in hepatitis C virus
(HCV) infection, cystic fibrosis (CF) and other diseases and reported
consolidated financial results for the quarter ended M...
|
|
|
Apr 15, 2010 |
Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial
|
22.2 KB |
|
| |
VIENNA, Austria, Apr 15, 2010 (BUSINESS WIRE) -- In conjunction with an oral presentation at the 45th Annual Meeting of
the European Association for the Study of the Liver (EASL) in Vienna,
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced
results from a Phase 1b clinical trial of the investigational oral
...
|
|
|
Apr 15, 2010 |
59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection
|
21.9 KB |
|
| |
VIENNA, Apr 15, 2010 (BUSINESS WIRE) -- In conjunction with an oral presentation at the 45th Annual Meeting of
the European Association for the Study of the Liver (EASL) in Vienna,
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
59 percent of patients overall who received a telaprevir-based
co...
|
|
|
Apr 7, 2010 |
New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy
|
22.2 KB |
|
| |
CAMBRIDGE, Mass., Apr 07, 2010 (BUSINESS WIRE) -- In a clinical trial known as PROVE 3 published in this week's New
England Journal of Medicine, treatment with telaprevir-based
regimens significantly increased rates of sustained viral response (SVR)
in patients with genotype 1 hepatitis C virus (HCV) infection who did
...
|
|
|
Apr 5, 2010 |
Vertex Pharmaceuticals Announces the Date of its First Quarter 2010 Financial Results Conference Call and Webcast
|
6.1 KB |
|
| |
CAMBRIDGE, Mass., Apr 05, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its
first quarter 2010 financial results on Wednesday, April 21, 2010 after
the financial markets close. The Company will host a conference call at
5:00 p.m. EDT.
The conference call will be webcast live and ma...
|
|
|
Mar 30, 2010 |
Vertex Pharmaceuticals Announces Webcast of its Presentation at Canaccord Adams' Hepatitis C Conference
|
6.0 KB |
|
| |
CAMBRIDGE, Mass., Mar 30, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
it will webcast its participation in an industry panel discussion at the
Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at
3:00 p.m. EDT.
The panel will be webcast live and may be acc...
|
|
|
Mar 16, 2010 |
Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting
|
12.9 KB |
|
| |
CAMBRIDGE, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
multiple abstracts related to the hepatitis C virus (HCV) protease
inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were
accepted for presentation at the 45th Annual Meeting of the
...
|
|
|
Mar 12, 2010 |
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
6.1 KB |
|
| |
CAMBRIDGE, Mass., Mar 12, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
it will webcast its presentations at the 22nd Annual ROTH
Growth Stock Conference on Tuesday, March 16, 2010 at 10:30 a.m. PDT
(1:30 p.m. EDT) and at the Barclays Capital 2010 Global Healthcare
Co...
|
|
|
Mar 1, 2010 |
Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies
|
18.5 KB |
|
| |
CAMBRIDGE, Mass., Mar 01, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
it is initiating the first clinical trial evaluating Vertex's lead
investigational hepatitis C virus (HCV) protease inhibitor, telaprevir,
dosed in combination with the company's lead investigational HCV ...
|
|
|
Feb 25, 2010 |
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
6.3 KB |
|
| |
CAMBRIDGE, Mass., Feb 25, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
it will webcast its presentations at the RBC Capital Markets Healthcare
Conference on Tuesday, March 2, 2010 at 1:35 p.m. EST and at the 30th
Annual Cowen Health Care Conference on Tuesday, March 9, 2010 ...
|
|
|
Feb 16, 2010 |
Vertex Pharmaceuticals Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013
|
7.8 KB |
|
| |
CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on
March 19, 2010 it will redeem the outstanding $32.1 million aggregate
principal amount of 4.75% Convertible Senior Subordinated Notes due
2013, in accordance with the terms of the indenture governing those
...
|
|
|
Feb 4, 2010 |
Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs
|
34.2 KB |
|
| |
CAMBRIDGE, Mass., Feb 04, 2010 (BUSINESS WIRE) -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update
on recent progress in its late-stage development programs in hepatitis C
virus (HCV) infection and cystic fibrosis (CF), reported consolidated
financial results for the year ended December 31,...
|
|
|
]assets/images/get_flash_player.gif){kind=small}
